5C-D
Pharmaceutical compound
From Wikipedia, the free encyclopedia
5C-D, also known as 4-methyl-2,5-dimethoxy-α-propylphenethylamine, is a putatively non-hallucinogenic serotonin 5-HT2 receptor agonist of the phenethylamine and α-propylphenethylamine families related to the 4C drug Ariadne (4C-D).[1][2]
- None
| Clinical data | |
|---|---|
| Other names | 4-Methyl-2,5-dimethoxy-α-propylphenethylamine; 2,5-Dimethoxy-4-methyl-α-propylphenethylamine; α-Propyl-Ariadne; 5C-DOM; α-Propyl-2C-D |
| Drug class | Serotonin 5-HT2 receptor agonist |
| ATC code |
|
| Identifiers | |
| |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C14H23NO2 |
| Molar mass | 237.343 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
At the serotonin 5-HT2A receptor, 5C-D is a potent and higher-efficacy partial agonist, with an EC50 of 291 nM and an Emax of 69%.[1][2] It is about half as potent as Ariadne as a serotonin 5-HT2A receptor agonist and has about 15% lower efficacy in activating the receptor in comparison.[1][2] 5C-D has also been shown to be a serotonin 5-HT2B receptor agonist.[2] In contrast to Ariadne and serotonergic psychedelics, 5C-D does not produce the head-twitch response, a behavioral proxy of psychedelic effects, in rodents.[2]
5C-D was first described in the scientific literature by Michael Cunningham and colleagues by 2023.[2] It was synthesized and assessed during structure–activity relationship (SAR) studies of Ariadne.[1][2]